P1677: DEFINING KEY QUALITY OF LIFE METRICS IN ACUTE MYELOID LEUKAEMIA AND HIGH RISK MYELODYSPLASTIC SYNDROME PATIENTS ENROLLED IN LARGE-SCALE UK NCRI AML TRIALS

Ижил төстэй зүйлс

• S131: A RANDOMISED ASSESSMENT OF THE SEQUENTIAL ADDITION OF THE KINASE INHIBITOR QUIZARTINIB TO INTENSIVE CHEMOTHERAPY IN OLDER ACUTE MYELOID LEUKAEMIA (AML) PATIENTS: RESULTS FROM THE NCRI AML18 TRIAL
  -н: Steven Knapper, зэрэг
  Хэвлэсэн: (2023-08-01)
• P503: A RANDOMISED TRIAL OF MOLECULAR MONITORING VERSUS STANDARD CLINICAL CARE IN YOUNGER ADULTS WITH ACUTE MYELOID LEUKAEMIA: RESULTS FROM THE UK NCRI AML17 AND AML19 STUDIES
  -н: Nicola Potter, зэрэг
  Хэвлэсэн: (2023-08-01)
• Transformation of myelodysplastic syndrome (MDS) to acute myeloid leukaemia (AML)
  -н: Goh, Chermaine Yu Zhen
  Хэвлэсэн: (2021)
• A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial
  -н: Burnett, A, зэрэг
  Хэвлэсэн: (2018)
• The addition of the mTORr inhibitor, Everolimus, to consolidation therapy in acute myeloid leukaemia: experience from the UK NCRI AML17 trial
  -н: Burnett, AK, зэрэг
  Хэвлэсэн: (2018)